MAIA Biotechnology (MAIA) grants 60,000 stock options to head of finance

Q: What did MAIA (MAIA) report in this Form 4 filing?

MAIA Biotechnology reported a stock option grant to its Head of Finance, Jeffrey C. Himmelreich, covering 60,000 shares of common stock at an exercise price of $1.39 per share, expiring on May 29, 2036.

Q: How many MAIA (MAIA) stock options were granted to the Head of Finance?

Jeffrey C. Himmelreich was granted 60,000 stock options. These options represent rights to purchase 60,000 shares of MAIA common stock, subject to a four-year vesting schedule under the company’s 2021 Equity Incentive Plan and an exercise price of $1.39.

Q: How do the MAIA (MAIA) stock options for the Head of Finance vest?

The options vest over four years. Twenty‑five percent vest on the first anniversary of the May 29, 2026 grant date, and the remaining 75% vest in equal monthly installments over the next 36 months, assuming continued service.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. reported that Head of Finance Jeffrey C. Himmelreich received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of $1.39 per share and expire on May 29, 2036.

The award was granted under the company’s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal monthly installments over the following 36 months.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Himmelreich Jeffrey C

Role Head of Finance

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	60,000	$0.00	--

Holdings After Transaction: Stock Options — 60,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 60,000 options Exercise price: $1.39 per share Expiration date: May 29, 2036 +2 more

5 metrics

Options granted 60,000 options Stock option award to Head of Finance

Exercise price $1.39 per share Exercise price of granted stock options

Expiration date May 29, 2036 Option term end date

Vesting cliff 25% at first anniversary Initial vesting of 4-year schedule

Remainder vesting 75% over 36 months Monthly vesting after first year

Key Terms

2021 Equity Incentive Plan, stock options, vesting schedule, underlying security

4 terms

2021 Equity Incentive Plan financial

"granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

stock options financial

"The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vesting schedule financial

"vest on a 4-year vesting schedule, with 25% of the options to vest"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

underlying security financial

"underlying_security_title: "Common Stock", underlying_security_shares: "60000.0000""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 08:49 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Himmelreich Jeffrey C

(Last)

(First)

(Middle)

50 CARLAND DRIVE

(Street)

ARDEN

NORTH CAROLINA

28704-8836

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Head of Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options	$1.39	05/29/2026		A		60,000		⁽¹⁾	05/29/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

	Jeffrey Himmelreich	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did MAIA (MAIA) report in this Form 4 filing?

MAIA Biotechnology reported a stock option grant to its Head of Finance, Jeffrey C. Himmelreich, covering 60,000 shares of common stock at an exercise price of $1.39 per share, expiring on May 29, 2036.

How many MAIA (MAIA) stock options were granted to the Head of Finance?

Jeffrey C. Himmelreich was granted 60,000 stock options. These options represent rights to purchase 60,000 shares of MAIA common stock, subject to a four-year vesting schedule under the company’s 2021 Equity Incentive Plan and an exercise price of $1.39.

What is the exercise price and term of the new MAIA (MAIA) stock options?

The options have a $1.39 exercise price and expire on May 29, 2036. This means the executive can buy MAIA common shares at $1.39 per share once vested, any time before the stated expiration date.

How do the MAIA (MAIA) stock options for the Head of Finance vest?

The options vest over four years. Twenty‑five percent vest on the first anniversary of the May 29, 2026 grant date, and the remaining 75% vest in equal monthly installments over the next 36 months, assuming continued service.

Under what plan were the MAIA (MAIA) stock options granted?

The options were granted under MAIA’s 2021 Equity Incentive Plan. This plan allows the company to issue equity-based awards, such as stock options, to employees and executives as part of their overall compensation and retention programs.